DMF May Protect Against Slow MS Worsening

Credibility

Interest

Key Takeaway

Dimethyl fumarate lowered a blood marker tied to long-term brain scarring and reduced non-inflammatory disability progression in relapsing-remitting MS, while rituximab did not.

What They Found

The study looked at two MS treatments over two years and measured two blood markers: sNfL, which reflects recent nerve damage, and sGFAP, which reflects ongoing support-cell (astrocyte) activity or scarring in the brain. Both treatments cut sNfL about half, suggesting they both reduce short-term inflammatory attacks that injure nerves, like putting out small fires quickly. Only dimethyl fumarate (DMF) caused a steady drop in sGFAP, which may mean it helps reduce longer-term scarring or ongoing damage inside the brain—think of it as helping with the slow, smoldering part of the fire. Patients on rituximab (RTX) did not have that drop in sGFAP, and they had a higher risk of getting worse in ways not explained by relapses or MRI activity (called PIRMA), meaning disability that progressed without clear new inflammation. Overall, DMF may offer extra benefit for the slower, non-inflammatory aspects of MS, while both drugs help stop acute inflammatory damage.

Who Should Care and Why

People with relapsing-remitting MS and their caregivers should care because the findings could affect choices about treatments that target long-term brain health, not just relapses. If you worry about preventing slow worsening or "silent" damage that doesn't show as flare-ups, DMF might offer added protection by lowering a marker linked to that process. Neurologists and MS care teams should note this when discussing goals of treatment—some patients prioritize preventing day-to-day decline even when relapses are controlled. Caregivers who help with daily tasks may see slower loss of function if a treatment helps the non-inflammatory progression the study measured. However, treatment choice also depends on side effects, other health issues, and personal priorities, so this is one piece of information to discuss with your care team.

Important Considerations

The study is limited to people with relapsing-remitting MS over two years, so we don’t know if results are the same in other MS types or longer follow-up. Blood markers like sGFAP and sNfL are helpful clues but are not perfect; they don’t directly show how a person feels or functions day-to-day. Also, while DMF was linked to less non-inflammatory progression in this trial, treatment choice should still consider side effects, individual response, and other medical factors.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials Specific Symptoms

Article Topics:

PIRMAbiomarkersdimethyl fumaratemultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of clinical and translational neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News